Recent Insights on the Medicinal Chemistry of Sickle Cell Disease

Author(s)

dos Santos, J. L. ^[1] ; Chin, C. M. ^[1]

Affiliation

^[1] Univ Estadual Paulista UNESP, Lapdesf Lab Pesquisa & Desenvolvimento Farm, Dept Farm & Med, Fac Ciencias Farmaceut, BR-14801902 Araraquara, SP - Brazil

• Document type: Review article
• Source: Current Medicinal Chemistry; v. 18, n. 15, p. 2339-2358, MAY 2011.
• Web of Science Citations: 7

Abstract

Sickle Cell Disease (SCD) is one of the most prevalent hematological diseases in the world. SCD is a genetic disease characterized by punctual mutation that basis on the exchange of glutamic acid to valine in a beta chain of hemoglobin. In deoxygenated state, the interaction among the beta chains leads to hemoglobin polymerization carrying out to deformation of cytoskeleton structure of red blood cells to a sickle shape. Currently, the treatment is performed with the antineoplasic drug hydroxyurea. This review summarizes current knowledge about possible targets and the approaches to discover new compounds to treat the SCD symptoms. Drug design based on therapeutical application and molecular modifications strategies will be discussed. (AU)

• FAPESP's process: 10/12495-6 - Optimization, synthesis and pharmacological evaluation of new drug candidates to treat the symptoms of sickle cell disease
• Grantee: Jean Leandro dos Santos
• Support Opportunities: Regular Research Grants